JPRN-UMIN000026493
Completed
Phase 1
Phase I study safety and immunogenicity of vaccination with XAGE1 long peptides in patients with advanced lung adenocarcinoma - XAGE1 cancer vaccine against advanced lung adenocaricinoma
Department of Immuno-Oncology, Kawasaki Medical School0 sites10 target enrollmentMay 22, 2017
ConditionsAdvanced lung adenocarcinoma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Advanced lung adenocarcinoma
- Sponsor
- Department of Immuno-Oncology, Kawasaki Medical School
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patients with HIV antibody positive. (2\) Patients with HCV antibody positive. (3\) Patients with HBs antigen or HBV\-DNA positive. (4\) Patients with active autoimmune disease. (5\) History of serious anaphylaxis induced by antibody preparation. (6\) Within 4 weeks after treatment with anticancer agent, immune suppressant, immune enhancer, cytokine therapy, radiotherapy or surgery for the primary disease. (7\) Patients with double cancer. (8\) Patients who need continuous systemic administration of adrenocorticosteroid. (9\) Refuse to use birth control including condom etc. from the time of obtaining the first consent to 24 weeks after the final administration of the study drug (except female after menopause (1 year or more after the last menstruation) and female/male after the operation for sterilization). (10\) Patients with active infection. (11\) Patients with psychosis or dementia. (12\) Patients who have received hematopoietic stem cell transplantation. (13\) Any other inadequacy for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase I Study: safety and immunogenicity of vaccination with XAGE1B long peptides combined with poly-ICLC in patients with pulmonary adenocarcinomalung carcinomanon small cell lung cancer1003866610029107NL-OMON45223eids Universitair Medisch Centrum30
Completed
Phase 1
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and RubellaRBR-9hckj4Bio-Manguinhos/Fiocruz/MS
Recruiting
Not Applicable
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDSPACTR201106000304583Swedish Institute for Infectious Disease Control24
Recruiting
Phase 1
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]CTIS2022-500706-18-01Oslo University Hospital Hf30
Completed
Phase 1
Safety, immunogenicity and dose finding for inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC)SARS-CoV-2.U07.1 COVID-19, virus identifiedU07.1 COVIIRCT20210206050259N1Organization of Defensive Innovation and Research135